• About Us
  • History

History

Autotelic Bio is researching and developing innovative new drugs with a sense of duty to improve the quality of life for patients around the world.

  • 2021 – Present
  • 2018 – 2020
  • 2015 - 2017

2021 – Present

2026

  • January.ATB-810, selected for the Ministry of SMEs and Startups’ Deep Tech Challenge Project

2025

  • June. Exclusive License and Technology Transfer Agreement with Aché (Brazil) for ATB-101

2024

  • April. ATB-101, exclusive license and supply agreement with Chinoin in Mexico

2023

  • Jun.Signed an MOU for Global New Drug Development of ATB-101 with Dream CIS and Tigermed
  • April.ATB-101, R&D Grant (Ministry of SMEs and Startups)
  • March.Youngjin Pharm-Autotelic Bio, Co-development Agreement

2022

  • September.ATB-610, R&D Grant (Korea Drug Development Fund)
  • May.ATB-101, Received IND Approval for Phase 3 Study
  • March.Series B Round
  • January.ATB-320, R&D Grant (Ministry of Trade, Industry and Energy)

2021

  • August.ATB-101, Phase 1 Study (DDI, PK) Completed Successfully
  • February.ATB-101, Received IND Approval for Phase 1 Study
  • ATB-301, Received IND Approval for Phase 1 Study
  • January.ATB-301, Agreement with Clinigen (UK)

2018 – 2020

2020

  • August.Strategic Investment by ST Pharm and 2 other Pharmaceutical Companies
  • April.ATB-301, R&D Grant (Ministry of Trade, Industry and Energy)
  • February.Series A Round with Stonebridge Ventures
  • January.Inno-biz Certified (Technology and Innovation-Oriented SMEs)

2019

  • January.Series A Round with Mega Investment & UTC Investment
  • November.Immuno-oncology R&D Grant (Medical Innovation Foundation)
  • October.Investment Agreement with Aju Pharm & KODIT
  • September.Expansion & New Location of Pankyo R&D Center
  • Jun.ATB-101, “K-Startup” R&D Grant (Ministry of SMEs and Startups)
  • May.TASO CMO Agreement with ST Pharm
  • April.ATB-301, Selected in “Pharm Navi” Project by MFDS (such as “Fast Track” regulation system in US FDA)
  • January.ATB-101, Tech Transfer and Investment Agreement with Jeil Pharm.

2018

  • September.Pankyo R&D Center Establishment
  • August.Angel Investment
  • July.Investment Agreement with TIPS
  • ATB-301, R&D Grant (Ministry of SMEs and Startups)
  • February.Venture Designation (Korea Technology Finance Corporation)
  • January.Company Name Change (Autotelic Korea → Autotelic Bio)

2015 – 2017

2017

  • September.ATB-101, R&D Grant (Ministry of SMEs and Startups)
  • Corporate R&D Center Accreditation

2015

  • November.Autotelic Korea Establishment

  • Privacy Policy
  • Headquarters.#302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si,
    Chungcheongbuk-do, 28610, Republic of Korea
  • R&D Center.#510 Signature Gwanggyo Knowledge Business Center 37, Poeun-daero 59beon-gil,
    Suji-gu, Yongin-si, Gyeonggi-do, 16864, Republic of Korea
    • T.043-233-9373
    • F.043-233-9374
    • E.info@autotelic.co.kr

Copyright © 2023 Autotelic Bio Inc. All rights reserved.